Expanded roles support the continued transition to a fully integrated biotechnology company focused on rare peripheral amyloid and neurodegenerative diseasesDUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE)
DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today